$KLRA News

Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M

Hengrui Pharma, Kailera Therapeutics To Present Two Abstracts At 86th Scientific Sessions Of The American Diabetes Association

Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36

Jefferies Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $48

Evercore ISI Group Initiates Coverage On Kailera Therapeutics with Outperform Rating

JP Morgan Initiates Coverage On Kailera Therapeutics with Overweight Rating, Announces Price Target of $30

KLRA stock has given up its prior gain. Kailera Therapeutics shares were trading higher amid post-IPO volatility.

KLRA stock has given up its prior gain. Kailera Therapeutics shares were trading higher amid post-IPO volatility.

Kailera Therapeutics shares are trading higher amid post-IPO volatility.

Kailera Therapeutics IPO Opens For Trade At $26/Share; IPO Priced At $16/Share On 39.06M Shares

Kailera Therapeutics IPO Indicating $22/Share On 840K Shares; IPO Priced At $16/Share On 39.06M Shares

Kailera Therapeutics IPO Indicating $21/Share On 750K Shares; IPO Priced At $16/Share On 39.06M Shares

Kailera Therapeutics IPO Indicating $24/Share On 559K Shares; IPO Priced At $16/Share On 39.06M Shares

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Reported Earlier, Kailera Therapeutics Prices $625M Initial Public Offering Of 39,062,500 Common Shares At $16 Each

Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results